Erhan Palaska

Erhan Palaska

Auto-generated profile, based on publicly available information

Erhan Palaska

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2002 in Il Farmaco
Verified
Journal Article
Closed access
EPErhan Palaska
Erhan Palaska
GŞGülay Şahin
Gülay Şahin
PKPelin Kelicen
Pelin Kelicen
NDN.Tuğba Durlu
N.Tuğba Durlu
GAGülçin Altinok
Gülçin Altinok

18 March 2008 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
EPErhan Palaska
Erhan Palaska
FAFirat Aydin
Firat Aydin
GUGülberk Uçar
Gülberk Uçar
DEDilek Erol
Dilek Erol

1 June 2001 in Arzneimittelforschung
Verified
Journal Article
Closed access
PDF file
GSGülay Sahin
Gülay Sahin
EPErhan Palaska
Erhan Palaska
PKPelin Kelicen
Pelin Kelicen
RDRümeysa Demirdamar
Rümeysa Demirdamar
GAGülçin Altinok
Gülçin Altinok
Sixteen 1-(1-naphthyloxy)acetyl-4-substi-tuted-3-thiosemicarbazides, 2-substituted amino-5-(1-naphthyloxy)methyl-1,3,4-oxadiazoles, 2-substitutedamino-5-(1-naphthyloxy) methyl-1,3,4-thiadia-zoles and 3-(1-naphthyloxy)methyl-4-substituted- l,2,4-triazole-5-thiones were synthesized. The structures of the compounds have been elucidated by UV, IR, 1H-NMR, 13C-NMR spectra and elemental analysis. The anti-inflammatory activities of the compounds were evaluated by carregeenan induced hind paw edema and air-pouch inflammation tests in mice. In carrageenan induced hind paw edema test, compounds 1a, 1d, 3d, 4a showed equivalent or higher activity compared to naproxen and phenylbutazone. In the air-pouch inflammatory model, compounds 1a, 1b, 1d, 2c, 3c, 3d, 4a and 4d showed marked anti-inflammatory activity. The ED50 values of these compounds ranged between 24-36 mg/kg. Side effects of the compounds on gastrointestinal system and kidneys were examined and none of the compound showed significant side effects. Synthese neuer 1 -Acylthiosemicarbazide, 1,3,4-Oxadiazole, 1,3,4-Thiadiazole und l,2,4-Triazole-3-thione und Evaluierung ihrer entzündungshemmenden Aktivität Sechszehn 1-(1-Naphthyloxy)acetyl-4-substituiterte-3-thiosemicarbazide, 2-substituierte Amino-5-(1-naphthyloxy)-methyl-1,3,4-oxadiazole, 2-substituierte Amino-5- (1 -naphthyloxy) methyl-1,3,4-thiadiazole und 3-(1-Naphthyloxy)me-thyl-4-substituierte-1,2,4-triazole-5-thione wurden dargestellt. Die Strukturaufklärung der Substanzen erfolgte mittels UV, IR, 1H-NMR, 13C-NMR und Elementaranalyse. Die entzündungshemmende Aktivität der Verbindungen wurde mit Hilfe des Carrageenin-Pfotenödems sowie des Lufttaschentests geprüft. Im Carageenin-Pfotenödem zeigten die Substanzen 1a, 1d, 3d und 4a gleiche bzw. stärkere Wirkung im Vergleich zu Naproxen und Phenylbutazon. Im Lufttaschenmodell zeigten die Substanzen 1a, 1b, 1d, 2c, 3c, 3d, 4a und 4d signifikante entzündungshemmende Aktivität. Die ED50-Werte lagen im Bereich 4-36 mg/kg. Darüber hinaus wurden die Nebenwirkungen im Magen-Darm-Trakt und in den Nieren untersucht. Die Substanzen zeigten keine signifikanten Nebenwirkungen.

22 January 2014 in Drug Research
Verified
Journal Article
Closed access
PDF file
GKG. Ş. Koç
G. Ş. Koç
OTO. U. Tan
O. U. Tan
GUG. Uçar
G. Uçar
EYE. Yıldırım
E. Yıldırım
KEK. Erol
K. Erol
EPE. Palaska
E. Palaska
28 new 3-(4-fluorophenyl)-5-aryl-N-substituted-4,5-dihydro-1H-pyrazole-1-carbothioamide derivatives were synthesized and evaluated in vitro for their monoamine oxidase (MAO) A and B inhibitory activity and selectivity. The derivatives substituted by halogen on the fifth position of pyrazole ring, inhibited MAO-A enzyme with a high selectivity index. On the other hand, compounds substituted with 2-naphthyl inhibited MAO-B enzyme with a moderate selectivity index. Docking studies were done to highlight the interactions of the most active derivative with the active site of MAO-A. In addition, in vivo antidepressant and anxiolytic activities of the compounds having selective MAO-A inhibitory effects, were investigated by using Porsolt forced swimming and elevated plus-maze tests respectively. 3-(4-Fluorophenyl)-5-(4-chloro­phenyl)-N-allyl-4,5-dihydro-1H-pyrazole-1-carbothio­amide has antidepressant, 3-(4-fluorophenyl)-5-(4-chlorophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide and 3-(4-fluoro­phenyl)-5-(4-bromophenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carbothioamide have anxiolytic activity.

21 July 2024 in Archiv der Pharmazie
Verified
Journal Article
Open access
EAEbru Kocak Aslan
Ebru Kocak Aslan
ASAysima Sezer
Aysima Sezer
TKTuba Tuylu Kucukkilinc
Tuba Tuylu Kucukkilinc
EPErhan Palaska
Erhan Palaska
Butyrylcholinesterase (BChE) is considered a promising therapeutic target for treating Alzheimer's disease due to the increase in the levels and activity of BChE in the late stage of the disease. In this study, a series of novel 1,2,4‐triazole derivatives bearing the naphthalene moiety linked to the benzothiazole, thiazole, and phenyl scaffolds via amid chain were designed and synthesized as potential and selective BChE inhibitors. The results of the inhibitory activity studies revealed that most of these compounds exhibited significant inhibitor potency on BChE. Compounds 35a (0.025 ± 0.01 μM) and 37a (0.035 ± 0.01 μM) displayed the most potent inhibitory activity, with excellent selectivity against BChE over acetylcholinesterase (SIBChE, 23,686 and 16,936, respectively) among the target compounds. The kinetics studies revealed that these compounds behaved with noncompetitive BChE inhibitors. Molecular docking studies indicated that 35a and 37a fit well into the active side of BChE. In addition, 35a and 37a also had the lowest cytotoxicity for human neuroblastoma cells (SH‐SY5Y), potential antioxidant capacity, moderate inhibition potency on amyloid‐β1‐42 aggregation, and significant neuroprotective effect against SH‐SY5Y cell injury induced by H2O2 and amyloid‐β1‐42. All results suggest that these compounds might be considered as promising new lead compounds in the drug discovery process for the treatment of late‐stage Alzheimer's disease.

5 June 2012 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
KŞKerem Şentürk
Kerem Şentürk
OTOya Unsal Tan
Oya Unsal Tan
SÇSamiye Yabanoğlu Çiftçi
Samiye Yabanoğlu Çiftçi
GUGülberk Uçar
Gülberk Uçar
EPErhan Palaska
Erhan Palaska